Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Via News Knowledge File

U.S. Securities and Exchange Commission

government agency80% conf.·synced Oct 15, 2026

U.S. federal regulatory agency overseeing securities markets

0
sourced metrics
1715
relationships
8
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Stated objectives

Make the U.S. the crypto capital of the world

source
stated

Incorporate crypto into retirement programs through regulatory guidance

source
target: regulatory framework by 2026-01-01 00:00:00stated

Provide whistleblower rewards totaling up to 30% of any successful recovery for original information

source
target: 30 stated

Work toward allowing the inclusion of alternative assets in self-directed retirement plans

source
stated

Encourage whistleblowers to provide original information about securities violations through rewards program offering up to 30% of successful recoveries

source
target: 30 stated

SEC Whistleblower program incentivizing persons with non-public information about Hercules Capital securities violations to come forward with original information in exchange for monetary rewards

source
target: up to 30% of successful SEC enforcement recovery stated

Cut off opportunities for market manipulators to exploit small overseas IPO listings and protect mom-and-pop investors from pump-and-dump schemes.

source
stated

Establish dedicated crypto custody rules for registered investment advisors, funds and BDCs under federal securities law

source
stated

Relationship graph · 1715 connections

regulates
1440
regulated by
232
Employs
14
subsidiary of
5
Covered by
4
contracted by
4
files with
3
governs
2
filed with
David B. Foshee
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com